Phase I Compare OS in Post-CyberKnife Radiosurgery Tx in 1-3 VS 4 or More Brain Metastases
The investigators will learn from this study if the CyberKnife radiosurgery (CK RS) treatment of patients with 1-3 versus 4 or more brain metastases results in the same overall survivals. The importance of this new knowledge will be to determine the treatment efficacy of CK RS with 1-3 versus 4 or more brain metastases. The outcome of this trial would give data to support either the continuation or modification of the CK RS treatment of patients with brain metastases.
|Study Design:||Observational Model: Cohort|
|Official Title:||A Comparison of Overall Survival Post-CyberKnife Radiosurgery Treatment of Patients With 1-3 Versus 4 or More Brain Metastases|
- Overall survival [ Time Frame: until death or the end of follow-up, whichever comes first. ] [ Designated as safety issue: No ]
|Study Start Date:||October 2014|
|Estimated Primary Completion Date:||December 2019 (Final data collection date for primary outcome measure)|
retrospective follow-up of patients treated since 2006
patients treated over a 5-year period from January 15, 2013 to December 31, 2017 and followed for at least one year thereafter
This is registry-based cohort study of patients with brain metastases treated at Stanford University Medical Center (SUMC) with CyberKnife radiosurgery (CK RS). It has two components: (1) a retrospective follow-up of patients treated since 2006, and (2) the accrual of a new cohort of patients treated over a 5-year period from January 15, 2013 to December 31, 2017 and followed for at least one year thereafter. The primary aim of this study is to estimate the effect of the number of brain tumor metastases on survival after adjusting for known risk factors for mortality.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01778764
|United States, California|
|Stanford University Cancer Institute|
|Stanford, California, United States, 94305|
|Principal Investigator:||Steven Chang||Stanford University|